Discontinued — last reported Q4 '25
Enbrel® (etanercept) — Total revenues
Products & Services · Total revenuesAmgen Enbrel® (etanercept) — Total revenues remained flat by 0.0% to $556.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 32.9%, from $829.00M to $556.50M. Over 2 years (FY 2023 to FY 2025), Enbrel® (etanercept) — Total revenues shows a downward trend with a -22.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market retention and effective lifecycle management, while a decrease indicates potential market share erosion due to patent expirations or the introduction of biosimilar competitors.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific flagship therapeutic product within...
Peer comparison
Comparable to revenue metrics for mature, branded pharmaceutical products or legacy blockbusters in the portfolios of large-cap biopharmaceutical peers.
amgn_segment_enbrel_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.14B | $1.29B | $862.00M | $1.05B | $924.25M | $924.25M | $924.25M | $924.25M | $829.00M | $829.00M | $829.00M | $829.00M | $556.50M | $556.50M | $556.50M | $556.50M |
| QoQ Change | — | +12.7% | -33.1% | +21.9% | -12.1% | +0.0% | +0.0% | +0.0% | -10.3% | +0.0% | +0.0% | +0.0% | -32.9% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | -8.1% | +7.2% | -12.1% | — | — | -10.3% | -10.3% | -10.3% | -10.3% | -32.9% | -32.9% | -32.9% | -32.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's enbrel® (etanercept) — total revenues?
- Amgen (AMGN) reported enbrel® (etanercept) — total revenues of $556.50M in Q4 2025.
- How has Amgen's enbrel® (etanercept) — total revenues changed year-over-year?
- Amgen's enbrel® (etanercept) — total revenues decreased by 32.9% year-over-year, from $829.00M to $556.50M.
- What is the long-term trend for Amgen's enbrel® (etanercept) — total revenues?
- Over 2 years (2023 to 2025), Amgen's enbrel® (etanercept) — total revenues has grown at a -22.4% compound annual growth rate (CAGR), from $3.70B to $2.23B.
- What does enbrel® (etanercept) — total revenues mean?
- The total sales revenue generated by the company's specific flagship therapeutic product for inflammatory diseases.